Paper Details

  1. Home
  2. Paper Details

Evidence of interferon beta-1a dose response in relapsing-remitting MS: the OWIMS Study. The Once Weekly Interferon for MS Study Group.

Author:

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Higher doses of interferon beta-1a, administered weekly, show a dose-effect relationship for both clinical and MRI variables in relapsing multiple sclerosis.
Paper Details　
Original Abstract of the Article :
OBJECTIVE: To compare efficacy of interferon beta-1a, 22 microg or 44 microg weekly, with placebo in relapsing MS. BACKGROUND: Uncertainty exists concerning the optimal dose regimen for interferon beta in relapsing-remitting MS. Many patients and physicians prefer the convenience and lesser side ef...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1212/wnl.53.4.679

データ提供：米国国立医学図書館（NLM）

Investigating the Dose Response of Interferon Beta-1a in Relapsing-Remitting MS

This study delves into the complex world of multiple sclerosis (MS), a chronic neurological disease, investigating the effectiveness of different doses of interferon beta-1a in managing relapsing-remitting MS. Imagine a desert landscape where the intricate network of the nervous system is vulnerable to a relentless sandstorm, like the attacks that characterize MS. This research explores different strategies for managing this storm, seeking to minimize its impact and improve the lives of those affected.

Finding the Right Dosage for MS Management

The study found that higher doses of interferon beta-1a were more effective in reducing the number and size of MS lesions compared to lower doses or placebo. This is like discovering that a stronger shield is more effective in protecting a desert caravan from a sandstorm, offering a greater level of protection. The findings suggest that a dose-dependent response exists for interferon beta-1a, providing valuable insights for optimizing treatment strategies.

Managing MS: A Continuous Journey

This research underscores the importance of ongoing research to improve our understanding of MS and develop more effective treatment strategies. It's like a continuous journey through a vast desert, where explorers constantly seek new pathways and solutions. The study's findings highlight the need for personalized approaches to MS management, tailoring treatment regimens to individual needs and maximizing the potential benefits of available therapies.

Dr.Camel's Conclusion

This research offers valuable insights into the effectiveness of interferon beta-1a in managing relapsing-remitting MS, highlighting the importance of tailoring treatment regimens to individual needs. It's like discovering a new oasis in the desert, providing a source of hope and potential for a brighter future for those battling this challenging disease. The study's findings underscore the need for continued research to develop even better treatments and therapies for MS, ensuring a more hopeful future for those affected by this debilitating disease.

Date :
  1. Date Completed 1999-10-29
  2. Date Revised 2019-05-14
Further Info :

Pubmed ID

10489026

DOI: Digital Object Identifier

10.1212/wnl.53.4.679

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.